NCT02704598 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Finks SW, Trujillo TC, Dobesh PP
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother. 2016 Jun;50(6):486-501. doi: 10.1177/1060028016632785. Epub 2016 Feb 25. Review.
Isaacs AN, Doolin M, Morse C, Shiltz E, Nisly SA
Medication utilization evaluation of dabigatran and rivaroxaban within a large, multi-center health system. Am J Health Syst Pharm. 2016 Mar 1;73(5 Suppl 1):S35-41. doi: 10.2146/sp150031.
Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet]
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. Available from http://www.ncbi.nlm.nih.gov/books/NBK344331/

Comparison of the Recanalization Rate and Incidence of Postthrombotic Syndrome in Patients With Lower-limb Deep Venous Thrombosis Treated With Rivaroxaban or Warfarin

Details for clinical trial NCT02704598

Clinical trial NCT02704598 - References